Company news
Outlook Therapeutics, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones
August 13, 2023
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023
July 31, 2023
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update
May 14, 2023
Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference
April 26, 2023
Outlook Therapeutics® Confirms It Has No Exposure to Silicon Valley Bank
March 12, 2023
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2023 and Provides Corporate Update
February 13, 2023
Outlook Therapeutics® to Present at the SVB Securities Global Biopharma Conference
February 6, 2023
Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence
January 18, 2023
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2022 and Provides Corporate Update
December 28, 2022
Outlook Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 22, 2022
Outlook Therapeutics® Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD
December 21, 2022
Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD
September 26, 2022
Outlook Therapeutics Strengthens Board of Directors with Appointment of Julia A. Haller, MD
August 14, 2022
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones
August 9, 2022
Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note
July 4, 2022
Outlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010
June 13, 2022
Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment for Wet AMD
May 30, 2022
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update
May 12, 2022
Outlook Therapeutics to Participate in Retina World Congress 2022
May 9, 2022
Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD
March 30, 2022
Outlook Therapeutics Bolsters Commercialization Expertise with Appointment of Alicia Tozier as Senior Vice President of Marketing and Market Access
March 2, 2022
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2022 and Provides Corporate Update
February 13, 2022
Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operations
February 7, 2022
Outlook Therapeutics Provides a Corporate Update and Business Outlook
January 24, 2022
Outlook Therapeutics Reports Financial Results for Fiscal Year 2021 and Provides Corporate Update
December 21, 2021
Outlook Therapeutics Announces Closing of $57.5 Million Bought Deal, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
November 28, 2021
Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $50 Million
November 22, 2021
Outlook Therapeutics Announces $10 Million Bought Deal Offering of Common Stock
November 22, 2021
Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference
November 12, 2021
Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial
September 27, 2021
Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at EURETINA Virtual 2021 Medical Conference
September 12, 2021
Outlook Therapeutics Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Corporate Update
August 12, 2021
Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
August 2, 2021
Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer
July 6, 2021
Outlook Therapeutics Announces Inclusion in the Russell 2000® Index
June 13, 2021
Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial
June 7, 2021
Outlook Therapeutics Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Corporate Update
May 13, 2021
Outlook Therapeutics to Host Virtual Clinical Day on May 20, 2021
May 11, 2021
Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
March 30, 2021
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2021 and Provides Corporate Update
February 15, 2021
Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
February 10, 2021
Outlook Therapeutics’ Recent Financing Secures Funding to Support ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Through Planned BLA Submission
February 3, 2021
Outlook Therapeutics Announces Closing of $35.0 Million Bought Deal
February 1, 2021
Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $35.0 Million
January 27, 2021
Outlook Therapeutics Announces $10.0 Million Bought Deal Offering of Common Stock
January 27, 2021
Outlook Therapeutics Reports Financial Results for Fiscal Year 2020 and Provides Corporate Update
December 22, 2020
Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
November 30, 2020
Outlook Therapeutics Announces Creation of Global Retina Advisory Council
November 18, 2020
Outlook Therapeutics Secures $10 Million in Additional Working Capital
November 4, 2020
Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
November 2, 2020
Calls
Decks
- Q3 2026 Earnings Presentation
Earnings · 16 slides · Aug 14, 2026
- Technical Presentation (January 2025)
Technical · 13 slides · January 2025
- Corporate Update (August 2021)
Corporate update · 21 slides · Aug 3, 2021